Ingredients, Nutrition Science and Disease: A Messy Map

August 6, 2019

In some of our recent work in the curcumin/turmeric category and emerging prebiotic category we came up against that wall that often faces the dietary supplement industry: “Your scientific evidence does not show an impact on disease, therefore your research is insufficient to sway scientific opinion, let alone public opinion, therefore your benefit-risk ratio is negligible, therefore you are irrelevant to the conversation”.

While my summation above might be a bit over-dramatic, the line of thinking and outcome is not. Too often, ingredient and more broadly, dietary supplement research gets totally dismissed because it doesn’t report on disease state. We in the industry know that it’s most often because we can’t, either due to the regulatory climate, or to the complications that nutrition science and nutritional ingredients inherently provide. Trying to do a placebo-controlled, double blind nutritional product study, where the ingredient might itself be or is closely related to a confounding dietary ingredient complicates the research. Couple that complexity with arguments such as ‘entourage effect’ and ‘whole food ‘considerations, as well as the confusing landscape of bioavailability and you have an environment where strategizing, executing and communicating an ingredient research program becomes almost impossibly daunting.

The converse criticism is also true, as often, ingredient and supplement research gets over-stated and becomes hyperbole, and therefore meaningless or out of context.

Credibly presenting the science on dietary ingredients is therefore challenging and frustrating, especially for those actually investing in the science. Working with the academic community is an alternative strategy for scientific advancement, although if not planned and negotiated carefully, documentation regarding product quality and characterization can go awry, rendering the resulting findings meaningless. Then there’s the issue of objectivity. Many academic researchers demand objectivity and while looking to industry to support the research, want complete autonomy with process, design and results. In the worst case, this devalues or removes the intellectual property value of the results, creating a neutral or negative ROI for the ingredient underwriting company.

Against this backdrop, not surprisingly, we have heard it recently observed that there is an overall decline in industry funded research. This is understandable from a short-term standpoint but is disappointing and a mid- and long-term mistake. We know that the regulatory landscape will continue to evolve with increasing pressure to adopt a master file system, at least in the United States, that begins to recognize IP on the part of those submitting New Dietary Ingredient (NDI) notifications. While the details are a long way from materializing, this environment and a re-thinking of DSHEA could create a huge market opportunity for companies even now thinking strategically about their research agendas. We are also seeing new structures in academic/industry relationships where industry gets what it needs: proper characterization and description of research materials, worthwhile participation in IP and publication context, and a true strategic research partner. Lastly, emerging advances in mechanistic science where nutritional ingredients are concerned, in the microbiome and beyond, is opening up new frontiers (yet to be fully substantiated in some cases) in structure function claim language.

These developments (ingredient IP protection through a notification process, new relationships with academia and the incorporation of novel mechanistic science to support claims) bode well for the future of ingredient science. Smart companies are developing their strategies now.

One closing thought: In our single ingredient associations, we have explored the concept of category-based research. Are there research parameters that a group of companies could align behind? Toxicity perhaps? In fact, we even proposed that to a group of CBD executives – could there be a broader group that would work on CBD safety for the purposes of an NDI submission? And for synbiotics, in theory, a probiotic supplier and prebiotic supplier could band together to do research, couldn’t they? Or would it take a brand to get exclusive ROI by being the one to initiate that combination ingredient program? This has not happened yet, but one can’t help wondering whether these approaches do in fact a possible category growth strategies.


Unlock the Power of Transparency: Schedule a Meeting Now

Ready to Illuminate Your Path?
Partner with Trust Transparency Today.

Get inTouch

Lori Diez

Lori Diez combines compassion and excellence to lead organizations to their next level. A small-town Texas childhood taught her the value of hard work and relationships, which she uses to foster teamwork that brings results that have transformed cultures and programs to their highest potential. Her successful career in pharmaceutical and nutraceutical sales leadership and event hosting has prepared her to deliver results as the COO of TrustTransparency, where she uses her industry knowledge to ensure that the company’s operations run smoothly as they support nutraceutical companies in their mission to help others. Lori’s passion for charity reflects her belief that individuals working together can change the world, no matter how small their contribution to the effort. This year, she looks forward to continuing over a decade of service at the Houston Livestock Show And Rodeo, where she will be the Chairman of the Livestock Committee.

Conference Handouts

Conference Handouts

CoQ10 Statin Associated Myaglia Meta Study Barry Tan 0618 Case Study

CoQ10 Statin Associated Myaglia Meta Study Barry Tan 0618 (1)

Statin Q10 Effect Case Study

Statin Q10 Effect Case Study

Schedule Consultation with Trust Transparency

Glynnda Steinford

Glynnda Steinford, Trust Transparency Consulting’s Director of Customer Relations, brings over four decades of healthcare experience to her vital role in client engagement and relationship building. Her diverse background spans from administering medical groups to impactful stints in pharmaceutical and nutraceutical sales, all underlined by her degree in Healthcare Administration.

At the heart of Glynnda’s work is her talent for nurturing long-term connections, a skill she leverages to enhance client experiences and partnerships within the consultancy. Beyond her professional commitments, she enjoys life’s simple pleasures, whether it’s her love for cats and cooking or her ventures into golf, always prioritizing cherished moments with family and friends. Her personal interests echo the dedication and warmth she extends in her professional network, making her an invaluable asset to the team.

Caiti Dowden

Caiti Dowden stands as a crucial pillar at Trust Transparency Consulting, bringing invaluable insight and expertise to her role as Senior Executive Assistant’ since her start in 2018. With an academic background from Sam Houston University and a career shift from education to the nutraceutical sphere in 2010, Caiti has cultivated a sharp acumen for dissecting industry trends and bolstering strategic decision-making.

Her transition from Data Analyst reflects her growth and deep understanding of the business landscape. Caiti’s commitment goes beyond professional excellence; she thrives on balance, drawing from her rich life outside of work to enhance her organizational contributions. Whether it’s family time, volunteering, or rooting for Houston’s sports teams, she believes in embracing experiences to fuel her professional creativity and insight.

In her current role, Caiti’s dedication to dynamic business analysis and operational support proves her to be an irreplaceable asset to our team, embodying the synergy of personal enrichment and professional success.

Pam Hilpert

Pam Hilpert, Chief of Staff at Trust Transparency Consulting, has been instrumental in the firm since its inception, leveraging her 17 years of accounting experience, including a significant tenure in the nutrition sector. Her collaboration with Scott Steinford spans various successful ventures, emphasizing her integral role in the company’s financial and strategic initiatives.

An alumnus of Sam Houston State University, Pam holds degrees in both Business Administration and Accounting, as well as an MBA, adding academic heft to her practical industry insights. Beyond her professional prowess, Pam is passionate about family, enjoys live music, delves into quilting, and volunteers at her church, reflecting her well-rounded life.

Her multifaceted expertise and longstanding dedication make Pam a cornerstone of Trust Transparency Consulting’s operational strength and team unity.

Scott Steinford

Scott Steinford, a trailblazer in strategic leadership, boasts a certified M&A background, having navigated companies from their genesis to industry prominence. His brainchild, Trust Transparency Consulting, born in 2007, stands as a testament to his dedication to ethical business practices and strategic foresight, offering industry stakeholders invaluable guidance.

Beyond founding and steering companies, Scott has enriched the business landscape with his insightful keynotes and prolific written contributions, emphasizing his commitment to elevating industry standards. His executive tenure shines in roles as CEO or President of for-profits like ZMC-USA and Doctor’s Best, extending to significant contributions in non-profit sectors.

Notably, Scott’s influence is a driving force in the CoQ10 market, where his leadership has significantly bolstered the ingredient’s global presence. His roles in various capacities, including as a New Hope Ambassador, keep the community informed, providing in-depth industry reports and insights.

An active advocate within professional associations and an Editorial Advisor for leading industry publications, Scott’s expertise is both recognized and sought after. With academic roots in Pre-Law and a Master’s in Law, his journey transcends textbooks, embodying real-world business acumen and transformative leadership.

Scott Steinford merges visionary entrepreneurship with principled leadership, creating a legacy of innovation, growth, and unwavering commitment to industry excellence.